| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNGR1 |
| Uniprot No | P15260 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 18-245aa |
| 氨基酸序列 | EMGTADLGPSSVPTPTNVTIESYNMNPIVYWEYQIMPQVPVFTVEVKNYG VKNSEWIDACINISHHYCNISDHVGDPSNSLWVRVKARVGQKESAYAKSE EFAVCRDGKIGPPKLDIRKEEKQIMIDIFHPSVFVNGDEQEVDYDPETTC YIRVYNVYVRMNGSEIQYKILTQKEDDCDEIQCQLAIPVSSLNSQYCVSA EGVLHVWGVTTEKSKEVCITIFNSSIKG |
| 预测分子量 | 27 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFNGR1重组蛋白的3篇参考文献示例(文献信息为模拟虚构，仅供参考)：
1. **文献名称**：*Crystal Structure of the Human Interferon Gamma Receptor 1*
**作者**：Walter, M.R. et al.
**摘要**：该研究解析了人IFNGR1重组蛋白的晶体结构，揭示了其与IFN-γ结合的分子机制，为设计靶向免疫调节药物提供结构基础。
2. **文献名称**：*Expression and Functional Analysis of Recombinant IFNGR1 in Immune Deficiency Models*
**作者**：Bach, E.A. et al.
**摘要**：通过大肠杆菌系统表达并纯化功能性IFNGR1重组蛋白，验证其在恢复IFN-γ信号通路缺陷细胞中的活性，探讨其在遗传性免疫疾病治疗中的潜力。
3. **文献名称**：*Recombinant IFNGR1 Fusion Protein Enhances Antitumor Immunity in Murine Models*
**作者**：Müller, M. et al.
**摘要**：构建IFNGR1重组融合蛋白，证明其可通过增强T细胞介导的免疫应答抑制肿瘤生长，为癌症免疫治疗提供新策略。
*注：以上文献信息为模拟示例，实际研究中请通过PubMed或学术数据库检索真实文献。*
Interferon-gamma receptor 1 (IFNGR1) is a critical component of the interferon-gamma (IFN-γ) signaling pathway, which plays a central role in innate and adaptive immunity. As a transmembrane protein, IFNGR1 forms a heterodimeric receptor complex with IFNGR2 to bind IFN-γ, a pro-inflammatory cytokine essential for host defense against intracellular pathogens, tumor surveillance, and immune regulation. The binding of IFN-γ triggers receptor dimerization, activating JAK-STAT signaling cascades that drive the expression of genes involved in antimicrobial activity, antigen presentation, and immune cell activation.
Recombinant IFNGR1 protein is engineered to mimic the extracellular domain of the native receptor, often produced in mammalian expression systems (e.g., CHO or HEK293 cells) or prokaryotic systems like *E. coli* to achieve high purity and bioactivity. Depending on the design, it may include functional domains for ligand binding (amino acids 1-229) and exclude the transmembrane/intracellular regions. Post-translational modifications such as glycosylation in mammalian systems enhance its stability and ligand-binding affinity.
This recombinant protein serves as a valuable tool for studying IFN-γ-receptor interactions, competitive inhibition of IFN-γ signaling in autoimmune diseases, and therapeutic exploration in hyperinflammatory conditions. It also aids in elucidating genetic defects in IFNGR1-linked immunodeficiencies, where mutations impair mycobacterial immunity. Additionally, soluble IFNGR1 has potential as a decoy receptor to modulate excessive IFN-γ responses in clinical settings. Quality assessments typically include ligand-binding assays, SDS-PAGE, and Western blotting to confirm structural integrity and function.
×
